MyMD Pharmaceuticals Enrolls First Client in Phase 2 Professional Trial of MYMD-1 as a Treatment for Delaying Aging and also Expanding Healthy Lifespan

MyMD Pharmaceuticals, Inc. MYMD stock price (” MyMD” or “the Company”), a medical phase pharmaceutical company committed to extending healthy life expectancy, today announced that the very first patient has been enlisted in the Firm’s Stage 2 professional trial of lead candidate MYMD-1, an oral immune regulator drug, as a treatment for postponing aging and broadening healthy and balanced lifespan.

The main endpoint for the Phase 2 double-blind, placebo-controlled medical trial is to achieve a reduction in the distributing levels of (TNF-α), growth death variable receptor I (TNFRI) and also IL-6. TNF-α and IL-6 are the proteins in the body that create inflammation and also assist activate the process of aging. The secondary measures of the trial will be the security, tolerability, and pharmacokinetics in this population of people.

” In a Phase 1 professional test of MYMD-1, we showed the medication’s statistically significant effectiveness in decreasing levels of TNF-α, a key player in triggering pathological aging, in the blood. The FDA has actually approved TNF-α reduction as the key endpoint for our Phase 2 research study, which our company believe settings us well for an effective Stage 2 outcome,” claimed Chris Chapman, M.D., Head Of State, Director as well as Principal Medical Police Officer of MyMD. “The initiation of individual enrollment in this research study advancements our objective to reduce the aging process, avoid loss of muscle mass cells in aging, limitation frailty, as well as prolong healthy and balanced life expectancy.”

MyMD has actually stated that there are no FDA-approved medicines for treating aging disorders as well as prolonging healthy and balanced life expectancy people, a market expected to be at the very least $600 billion by 20251 according to a significant financial investment bank. TNF-α blockers are one of the most prescribed medications by earnings, an international market of around $40 billion annually,2 as well as, according to Nature Aging journal,3 a downturn in aging that would enhance life span by one year deserves $38 trillion as well as by ten years deserves $367 trillion.

Along with aging, MYMD-1’s distinct activity in controling the immune system and treating chronic swelling is being developed for the treatment of autoimmune condition, including rheumatoid arthritis (RA), multiple sclerosis (MS), diabetes mellitus, and inflammatory bowel condition.

” We mean to begin creating methods for a Phase 2 pilot research of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman kept in mind. “The rising frequency of rheumatoid arthritis and other autoimmune and inflammatory diseases are driving demand for TNF preventions like MYMD-1, and our company believe our orally provided medication with very low poisoning would be turbulent to the $60 billion market for RA if approved by the FDA for this indicator.”

Rheumatoid arthritis impacts about 40 million people globally.4.

Concerning MYMD-1.

Originally established for autoimmune illness, MYMD-1’s key objective is to slow down the aging process, protect against sarcopenia as well as frailty, and extend healthy life expectancy. Due to the fact that it can go across the blood-brain barrier as well as access to the main nervous system (CNS), MYMD-1 is also placed to be a feasible treatment for brain-related conditions. Its device of action and efficiency in diseases including multiple sclerosis (MS) as well as thyroiditis have been examined through cooperations with a number of academic institutions. MYMD-1 is also showing promise in pre-clinical studies as a potential treatment for post- COVID-19 problems and as an anti-fibrotic and anti-proliferation therapeutic.

MYMD-1 has revealed effectiveness in pre-clinical research studies in managing the immune system by carrying out as a discerning inhibitor of tumor death factor-alpha (TNF-α), a driver of persistent inflammation. Unlike other treatments, MYMD-1 has been received these pre-clinical research studies to precisely obstruct TNF-α when it becomes overactivated in autoimmune diseases and also cytokine storms, however not block it from doing its normal task of being an initial -responder to any kind of regular type of modest infection. MYMD-1’s convenience of dental application is one more differentiator compared to currently readily available TNF-α blockers, all of which need shipment by injection or mixture. No approved TNF inhibitor has ever been dosed orally. On top of that, the drug is not immunosuppressive and also has actually not been revealed to cause the severe adverse effects usual with standard therapies that treat inflammation.

Regarding MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical phase pharmaceutical business devoted to prolonging healthy lifespan, is concentrated on developing 2 novel healing platforms that treat the root causes of condition rather than just resolving the symptoms. MYMD-1 is a medication platform based upon a medical phase tiny molecule that regulates the immune system to manage TNF-α, which drives chronic swelling, as well as other pro-inflammatory cell signaling cytokines. MYMD-1 is being established to delay aging, rise longevity, and also treat autoimmune conditions and COVID-19- associated anxiety. The Firm’s second medication system, Supera-CBD, is being established to deal with chronic discomfort, dependency as well as epilepsy. Supera-CBD is an unique artificial derivative of cannabidiol (CBD) as well as is being developed to deal with as well as surpass the swiftly growing CBD market, that includes both FDA approved medications and also CBD items not presently managed as drugs. For more details, check out